Related Experiment Video
Updated: Jun 3, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
Azacytidine for the treatment of myelodysplastic syndromes in the elderly
Maria Diez Campelo1, Regina Garcia Delgado, Ana Cristina Godoy Molias
1Department of Hematology, Hospital Universitario, Salamanca, Spain.
Abstract:
The management of myelodysplastic syndromes (MDS) in elderly patients is a significant clinical problem. The therapeutic options range from observation alone for patients with low-risk disease, lenalidomide for patients with 5q-syndrome, to 5-azacytidine (5-AZA) for patients with higher risk of disease. In this paper, we summarize the clinical course of three patients with high-risk MDS treated with 5-AZA as well as the management and supportive care measures for adverse events. As expected, based on available clinical trials data, the agent resulted in clinical and hematological improvement in these patients with acceptable side effects. 5-AZA is an attractive option for elderly patients with high-risk MDS.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Drug Dosing: Geriatric Patients
Alzheimer's Disease: Treatment
Pharmacodynamics in Geriatric Patients: Effects of Age
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Treatment Resistent Cancers